Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

Background: At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiv...

Full description

Bibliographic Details
Main Authors: GJ Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser, Aileen Clarke
Format: Article
Language:English
Published: NIHR Journals Library 2017-09-01
Series:Health Technology Assessment
Subjects:
multiple sclerosis
clinically isolated syndrome
beta interferon
glatiramer acetate
systematic review
economic evaluation
Online Access:https://doi.org/10.3310/hta21520

Internet

https://doi.org/10.3310/hta21520

Similar Items